These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21682551)

  • 1. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
    Corsini A; Ceska R
    Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.
    Gosho M; Tanahashi M; Hounslow N; Teramoto T
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):635-46. PubMed ID: 26104032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):51-65. PubMed ID: 24156555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
    Yee LL; Wright EA
    Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin: a new HMG-CoA reductase inhibitor.
    Wensel TM; Waldrop BA; Wensel B
    Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
    Gotto AM; Moon J
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
    Baker WL; Datta R
    Adv Ther; 2011 Jan; 28(1):13-27. PubMed ID: 21170619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
    Ahmad H; Cheng-Lai A
    Cardiol Rev; 2010; 18(5):264-7. PubMed ID: 20699675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin.
    Mukhtar RY; Reid J; Reckless JP
    Int J Clin Pract; 2005 Feb; 59(2):239-52. PubMed ID: 15854203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitavastatin - from clinical trials to clinical practice.
    Masana L
    Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
    Barrios V; Escobar C; Zamorano JL
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
    Catapano AL
    Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.